Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionMARKOWITZ, Martin; NGUYEN, Bach-Yen; CAMPBELL, Havilland et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 3, pp 350-356, issn 1525-4135, 7 p.Article

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus : a phase II randomised controlled trial. CommentaryCAHN, Pedro; SUED, Omar; HARVEY, Charlotte M et al.Lancet (British edition). 2007, Vol 369, Num 9569, issn 0140-6736, 1235-1236,1261-1269 [11 p.]Article

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)GOTUZZO, Eduardo; MARKOWITZ, Martin; TEPPLER, Hedy et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 1, pp 73-77, issn 1525-4135, 5 p.Article

Effects of Omeprazole on Plasma Levels of RaltegravirIWAMOTO, Arian; WENNING, Larissa A; AZROLAN, Neal et al.Clinical infectious diseases. 2009, Vol 48, Num 4, pp 489-492, issn 1058-4838, 4 p.Article

Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. CommentaryCOPLAN, Paul M; COOK, John R; CARIDES, George W et al.Clinical infectious diseases. 2004, Vol 39, Num 3, pp 426-436, issn 1058-4838, 11 p.Article

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsERON, Joseph J; YOUNG, Benjamin; KUMAR, Princy N et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, issn 0140-6736, 12 p.Article

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLENNOX, Jeffrey L; DEJESUS, Edwin; BARNARD, Richard J. O et al.Lancet (British edition). 2009, Vol 374, Num 9692, pp 796-806, issn 0140-6736, 11 p.Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudineHAAS, David W; ARATHOON, Eduardo; BENETUCCI, Jorge et al.AIDS (London). 2000, Vol 14, Num 13, pp 1973-1978, issn 0269-9370Article

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected PatientsRIZK, Matthew L; YAMING HANG; LUO, Wen-Lin et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3101-3106, issn 0066-4804, 6 p.Article

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment- Experienced Patients with Drug- Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsSTEIGBIGEL, Roy T; COOPER, David A; YENI, Patrick et al.Clinical infectious diseases. 2010, Vol 50, Num 4, pp 605-612, issn 1058-4838, 8 p.Article